Steven Lin, DO
Neurology · Staten Island, NYNPI 1922338334
Payments from drug & device makers
Across 89 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$313
- Supernus Pharmaceuticals, Inc.$235
- Teva Pharmaceuticals USA, Inc.$183
- Jazz Pharmaceuticals Inc.$143
- Bausch Health US, LLC$125
- Amgen$92
- plus $484 from 18 others
What the payments were for
- Speaking & faculty fees$121%
- Food & beverage$1,56299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 12 | $313 |
| Supernus Pharmaceuticals, Inc. | 17 | $235 |
| Teva Pharmaceuticals USA, Inc. | 13 | $183 |
| Jazz Pharmaceuticals Inc. | 7 | $143 |
| Bausch Health US, LLC | 8 | $125 |
| Amgen | 4 | $92 |
| Pfizer | 4 | $63 |
| AstraZeneca | 2 | $45 |
| Medtronic | 2 | $40 |
| Arbor Pharmaceuticals, Inc. | 3 | $39 |
| Scilex Pharmaceuticals Inc. | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| GE HealthCare | 2 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $22 |
| Sanofi | 1 | $22 |
| Strongbridge US Inc. | 1 | $21 |
| Nevro Corp. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| CSL Behring | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Acorda Therapeutics, Inc | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$123
How this compares
$1,573 in reported general payments places this provider in the 50th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 22 | $25,151 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,813 |
| Gabapentin | 254 | $3,109 |
| Fluocinonide | 13 | $2,030 |
| Levetiracetam | 31 | $1,694 |
| Naproxen | 17 | $780 |
| Memantine Hcl | 31 | $697 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 13 | $651 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 30 | $595 |
| Donepezil Hcl | 33 | $466 |
| Sumatriptan Succinate | 64 | $438 |
| Topiramate | 11 | $417 |
| Lamotrigine | 25 | $357 |
| Primidone | 16 | $325 |
| Pregabalin | 19 | $324 |
Paid to pharmacies, not to this prescriber.
Other neurology in Staten Island
- Allan PerelStaten Island$1.8M
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.